MA20150035A1 - Dérivés des pyridazin-3(2h)-ones, préparation , activités pharmacologiques et biologiques - Google Patents
Dérivés des pyridazin-3(2h)-ones, préparation , activités pharmacologiques et biologiquesInfo
- Publication number
- MA20150035A1 MA20150035A1 MA36055A MA36055A MA20150035A1 MA 20150035 A1 MA20150035 A1 MA 20150035A1 MA 36055 A MA36055 A MA 36055A MA 36055 A MA36055 A MA 36055A MA 20150035 A1 MA20150035 A1 MA 20150035A1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmacological
- pyridazin
- ones
- biological activities
- derivatives
- Prior art date
Links
- 230000000144 pharmacologic effect Effects 0.000 title abstract 3
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title abstract 2
- 230000004071 biological effect Effects 0.000 title abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 2
- YQQSRZSUGBETRS-UHFFFAOYSA-N 1h-pyridazine-6-thione Chemical class SC1=CC=CN=N1 YQQSRZSUGBETRS-UHFFFAOYSA-N 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 230000003276 anti-hypertensive effect Effects 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 230000003177 cardiotonic effect Effects 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 230000000506 psychotropic effect Effects 0.000 abstract 1
- 150000004892 pyridazines Chemical class 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 230000001624 sedative effect Effects 0.000 abstract 1
- 238000011287 therapeutic dose Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000002110 toxicologic effect Effects 0.000 abstract 1
- 231100000027 toxicology Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Les dérivés oxygénés de la pyridazine sont connus en thérapeutique pour la richesse de leurs potentiels pharmacologique : antihypertenseur et cardiotonique. Des propriétés antibactériennes, anti-inflammatoires et psychotropes sont également mentionnées dans la littérature. De ces considérations, résulte l'idée de synthétiser et d'étudier de nouvelles séries dérivées des pyridazin-3(2h}-ones et des pyridazin3( 2h)-thiones sur le plan toxicologique, et d'explorer leurs activités pharmacologiques et biologiques. Une étude récente a démontrée que des produits déjà synthétisés ne sont pas toxiques aux doses thérapeutiques et qu'ils sont doués d'effets sédatifs, myorelaxant et anxiolytique, ils ont montré aussi une activité antiinflammatoire, analgésique, antifongique et antimicrobienne.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MA36055A MA36055B1 (fr) | 2013-06-27 | 2013-06-27 | Dérivés des pyridazin-3(2h)-ones, préparation , activités pharmacologiques et biologiques |
| PCT/MA2013/000039 WO2014209094A1 (fr) | 2013-06-27 | 2013-12-05 | Dérivés de pyridazin-3(2h)-one, préparation, activités pharmacologiques et biologiques |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MA36055A MA36055B1 (fr) | 2013-06-27 | 2013-06-27 | Dérivés des pyridazin-3(2h)-ones, préparation , activités pharmacologiques et biologiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA20150035A1 true MA20150035A1 (fr) | 2015-02-27 |
| MA36055B1 MA36055B1 (fr) | 2015-12-31 |
Family
ID=49883182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36055A MA36055B1 (fr) | 2013-06-27 | 2013-06-27 | Dérivés des pyridazin-3(2h)-ones, préparation , activités pharmacologiques et biologiques |
Country Status (2)
| Country | Link |
|---|---|
| MA (1) | MA36055B1 (fr) |
| WO (1) | WO2014209094A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3125244A1 (fr) * | 2019-01-04 | 2020-07-09 | Jiangsu Hengrui Medicine Co., Ltd. | Derive de 6-oxo-1,6-dihydropyridazine, son procede de preparation et son utilisation medicale |
| CN112996776B (zh) * | 2019-02-20 | 2024-03-15 | 福建盛迪医药有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| CN113939295B (zh) * | 2019-03-20 | 2025-05-16 | 金翅雀生物公司 | 哒嗪酮及其使用方法 |
| WO2022037647A1 (fr) * | 2020-08-19 | 2022-02-24 | 江苏恒瑞医药股份有限公司 | Forme cristalline d'inhibiteur sélectif de nav et son procédé de préparation |
-
2013
- 2013-06-27 MA MA36055A patent/MA36055B1/fr unknown
- 2013-12-05 WO PCT/MA2013/000039 patent/WO2014209094A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MA36055B1 (fr) | 2015-12-31 |
| WO2014209094A1 (fr) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38391A1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
| MY192354A (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
| CA2925624C (fr) | Inhibiteurs de nicotinimide substitues de btk et leur preparation et utilisation dans le traitement du cancer, d'inflammations et des maladies auto-immunes | |
| MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| BRPI0810641A2 (pt) | "compostos farmacêuticos". | |
| MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
| PH12016500531B1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| MA20150035A1 (fr) | Dérivés des pyridazin-3(2h)-ones, préparation , activités pharmacologiques et biologiques | |
| EA201000365A1 (ru) | Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза | |
| MA38080A1 (fr) | Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 | |
| PH12015502630A1 (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors | |
| NZ754764A (en) | Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses | |
| MA35748B1 (fr) | Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines | |
| WO2010086860A3 (fr) | Composés multifonctionnels neuroprotecteurs et compositions pharmaceutiques les comprenant | |
| MX2015016771A (es) | Compuestos de carbazol carboxamida utiles como inhibidores de cinasa. | |
| EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
| MA44948A1 (fr) | Inhibiteurs de bace 1 | |
| MA37691B1 (fr) | 5-amino[1,4]thiazines comme inhibiteurs de bace1 | |
| MA37763A1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
| WO2017134685A3 (fr) | Nouveaux composés hydrazino utilisés comme inhibiteurs de btk | |
| EA201491026A1 (ru) | Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1 |